Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer - Wikidata - wikimedia - TriplyDB

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

http://www.wikidata.org/entity/Q35967139

about

Exposure to bisphenol A correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro Splice Variants of Androgen Receptor and Prostate Cancer A sting in the tail: the N-terminal domain of the androgen receptor as a drug target When Prostate Cancer Circulates in the Bloodstream Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer Targeting molecular resistance in castration-resistant prostate cancer Abiraterone in prostate cancer: a new angle to an old problem Abiraterone in the treatment of metastatic castration-resistant prostate cancer Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223 Androgen receptor on the move: boarding the microtubule expressway to the nucleus The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer Chemotherapy and its evolving role in the management of advanced prostate cancer Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy Targeting the adaptive molecular landscape of castration-resistant prostate cancer Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability.Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Emerging data on androgen receptor splice variants in prostate cancer Using circulating tumor cells to inform on prostate cancer biology and clinical utility Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves.Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Prognostic Significance and Functional Role of CEP57 in Prostate Cancer Androgen receptor splice variants determine taxane sensitivity in prostate cancer.ERG induces taxane resistance in castration-resistant prostate cancer The link between androgen receptor splice variants and castration-resistant prostate cancer.Single cell dynamic phenotyping.Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.PRUNE is crucial for normal brain development and mutated in microcephaly with neurodevelopmental impairment Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.Nanoways to overcome docetaxel resistance in prostate cancer.The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.Practical guide to the use of abiraterone in castration resistant prostate cancer.

P2860

Q21132302-08C316F1-36E7-40C4-8CAE-B1B916C97096 Q26740592-E7DF1098-6370-4DF2-98B2-066A8F3CC356 Q26747094-CC366EBA-E200-4535-8027-6B0849C4E352 Q26768470-4AB9DE07-E54B-41BC-9749-3FF55B1C9077 Q26769599-215775D8-428D-4B1D-8303-C701F5D3FD53 Q26773634-119A61D3-00A7-4ACE-ADF5-CDF7B6C8CCED Q26795445-AE741AC7-55C3-4B0D-83F0-0723C35DDDF5 Q26828810-D62FB7B0-B2AA-4705-8AC9-54555DA956A5 Q26853635-E8E59E60-BBDD-4A89-9841-408435781250 Q26858922-53E1A135-1F77-413B-B0A3-87AD4898654D Q26861575-8DDFD61E-533C-49DA-BF04-B07907BAD004 Q26862560-0E3F9964-4AC4-4354-99EC-45AF2571B70A Q27008262-73953D88-013B-4B91-B090-4D0C0133806E Q27008883-AF133944-EF3E-4D06-868D-AC82C1F31A8F Q27022715-CF83683C-4CD2-4FEB-B74B-B6B90E9D2CA2 Q27022821-A7D583B5-82D5-4A40-9644-7EEBAEC53DAF Q27321639-637F686C-90CC-4767-9AE1-553B075F3CD3 Q27334142-B21D7B54-058C-445A-91C7-46662A26D6AE Q28075965-83976A49-28A8-445E-968E-C54814E81B57 Q28077830-C61DC662-9917-4774-AA87-CB90FB3CF73A Q28083261-0AD24BD3-939F-4F71-9505-9036A84D22EF Q28482878-009383FD-5700-48C4-9D79-22FA1EB252D0 Q28555163-9539E243-E82B-4EEC-A74D-4408A09B24AA Q28607383-56D0F02A-CD76-4F88-A66B-FF639584AEB4 Q30244818-B67BE4C4-68F8-4F19-BE3F-AE47DA5827F6 Q30361019-018F17E9-2B95-4670-BD8F-D71C13D9A217 Q30577613-5E6C1362-2D45-4BA9-AEA9-2A222F6D6015 Q30602046-DB6044BD-3031-492C-B9F9-0E2562A241FF Q30618562-B9A33784-4AF8-43BB-8B41-CE55CDDCCEEA Q30818964-B53D7AF5-82B2-473C-A54A-B0AE45A3E9E7 Q30835493-69218CBC-30FF-4718-A480-6F99BE2D5744 Q32884505-08E58867-B90D-4C29-807F-F05D79A9CF07 Q33408024-A719D98E-2010-4795-AEEA-1D919B4C7FCA Q33621403-633D4824-8997-4867-A18C-BE9C6EF0200A Q33702987-E328B858-B5D5-4F5E-B9A6-0CAD7E6AAA92 Q33775723-16C6582D-7BDD-4D6A-A9FE-464B1B24579A Q33789192-3EE81748-618C-4B69-ADEE-1150105FDF11 Q33909084-0145BAA7-DD42-4E49-A597-8694CBD9B8E1 Q33946666-092AA902-7CFE-4A4C-AB9E-77CAEF871047 Q34070638-F84FFE76-5AAE-44A7-86ED-C26F84BB5EF4

P2860

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

http://www.wikidata.org/entity/Q35967139

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Taxane-induced blockade to nuc ...... in metastatic prostate cancer

@ast

Taxane-induced blockade to nuc ...... in metastatic prostate cancer

@en

type

label

Taxane-induced blockade to nuc ...... in metastatic prostate cancer

@ast

Taxane-induced blockade to nuc ...... in metastatic prostate cancer

@en

prefLabel

Taxane-induced blockade to nuc ...... in metastatic prostate cancer

@ast

Taxane-induced blockade to nuc ...... in metastatic prostate cancer

@en

P1433

Q35967139-90B650F0-753A-46E8-8708-5E76A73E2C21

P1476

Q35967139-44B3CEC8-6D8C-4423-8BA4-6EA5685B78BE

P2093

Q35967139-0F4E72F7-601D-42B5-9F38-50223EE9AD29

Q35967139-148DBBA9-93C7-4A99-BD4D-82E63D140DA3

Q35967139-2B6215AF-C4E1-4656-AEF9-EEFB50A5BB9D

Q35967139-2C2AAAAE-51C3-4C75-9332-BC7C0468D1CE

Q35967139-3E61615D-99E9-4D81-A04F-183C5656AD75

Q35967139-5174D6C2-3150-497E-9B98-3F0F20CC6762

Q35967139-71913C8C-29D4-4B31-8D0E-555FF4753300

Q35967139-8501583C-5EE4-414C-829A-070839DFC432

Q35967139-D900F7A6-3756-4082-BF4D-C07E8E234759

Q35967139-E815951D-523D-4CB4-B7DE-4352B15FC32A

P2860

Q35967139-02657A3B-56CC-4FBF-B5A7-FEFC9313B8B0

Q35967139-066706FD-E048-4548-9764-4CB1A59B6763

Q35967139-0728ACD9-2896-4F9F-A36A-ABEA6FDB078B

Q35967139-0C51F3D9-272E-4D86-BAF7-97CCDA0DA6FF

Q35967139-148CD800-425E-44FE-9341-DE533E921F76

Q35967139-22CC61AF-529B-4DE5-9B67-06A5EC748584

Q35967139-25412CCA-E73D-4FEB-80B5-A27974099BCA

Q35967139-345885FF-C7BF-437E-968E-BCEA190530D2

Q35967139-3F28E09D-FDF2-41B8-8764-82E00F0035B9

Q35967139-58EF97F0-D098-4688-A7DC-2003EC61266D

P304

Q35967139-94310404-873E-4BFF-802E-05A03B6BADFB

P31

Q35967139-EE7AF8DF-10F4-4803-910B-4956F077FE12

P356

Q35967139-E9D1C768-CB24-4EEC-AD3F-CD622F3CF412

P407

Q35967139-8CCA7206-8403-47E3-9D67-2E078963322B

P433

Q35967139-007B4BB3-B44E-43E6-A65C-18CCBFE24353

P478

Q35967139-EF1656C7-BA1D-4EE0-8380-5506B2525106

P50

Q35967139-E4C38114-09BC-4CC0-9FCA-280BF02DB6FF

P577

Q35967139-8344307A-020A-4F76-AC5B-20AC70198355

P698

Q35967139-BCFEE90D-03E2-4B93-A0DF-0FD785D4ED05

P932

Q35967139-49AC9CAE-1D97-4496-B5EF-DCBF31F25B57

P356

0008-5472.CAN-11-1417

P1433

Cancer Research

P1476

Taxane-induced blockade to nuc ...... in metastatic prostate cancer

@en

P2093

Ada Gjyrezi

http://www.w3.org/2001/XMLSchema#string

Benjamin P Levy

http://www.w3.org/2001/XMLSchema#string

Chantal Chanel-Vos

http://www.w3.org/2001/XMLSchema#string

David M Nanus

http://www.w3.org/2001/XMLSchema#string

Maria Thadani-Mulero

http://www.w3.org/2001/XMLSchema#string

Matthew S Loftus

http://www.w3.org/2001/XMLSchema#string

Medha S Darshan

http://www.w3.org/2001/XMLSchema#string

Neil H Bander

http://www.w3.org/2001/XMLSchema#string

Paraskevi Giannakakou

http://www.w3.org/2001/XMLSchema#string

Ruoqian Shen

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Molecular determinants of resistance to antiandrogen therapy

Targeted treatment of prostate cancer

Microtubules as a target for anticancer drugs

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

The development of androgen-independent prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

P304

6019-6029

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-1417

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21799031

http://www.w3.org/2001/XMLSchema#string

P932

3354631

http://www.w3.org/2001/XMLSchema#string